Quantcast

NuSil Technology Debuts High-Consistency Fluorosilicone Grease

May 21, 2011

Swell-resistant MED-6731 is ideal for healthcare applications

Carpinteria, CA (PRWEB) May 19, 2011

NuSil Technology LLC (http://www.nusil.com), the global leader in silicone materials for the healthcare and pharmaceutical industries, introduces a new low-flow, high-consistency fluorosilicone grease for healthcare applications.

MED-6731 is a silicone grease composed of a dimethyl methyltrifluoropropylsiloxane copolymer. It can be used in applications that require a solvent-resistant grease and may be used as a high-vacuum grease around glass, ceramic and ground glass joints. A fluorosilicone fluid may be used for applications in which dimethylpolysiloxane grease has compatibility issues with silicone rubber components; however, if migration is a concern, MED-6731 provides an excellent solution.

“Most components are molded from a dimethyl silicone, so it is important to have a lubricant that, when it comes into contact, will not absorb into or swell the component,” said Brian Nash, vice president of sales and marketing. “MED-6731 is a great option for a lubricant that provides the desired swell resistance.”

Cytotoxicity and trace metals testing are performed on each lot of MED-6731. A Master Access File and biological testing will be filed with the U.S. FDA.

For more information, please contact NuSil, or visit http://www.nusil.com/products/healthcare/unrestricted.

About NuSil Technology LLC

NuSil is a leading formulator of silicone compounds for healthcare, aerospace, electronics and other applications requiring precise, predictable materials performance. ISO 9001-certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and provides on-site, in-person application engineering support worldwide. More information about NuSil Technology LLC can be found at http://www.nusil.com

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/5/prweb8393867.htm


Source: prweb



comments powered by Disqus